DeepHow has launched PharmaCloud, a good manufacturing practice (GMP)-compliant cloud environment developed specifically to standardise AI-driven operator training in pharma manufacturing.
iRegene Therapeutics has received regenerative medicine advanced therapy (RMAT) designation from the US Food and Drug Administration (FDA) for its lead product, NouvNeu001, aimed at treating Parkinson’s disease.
AstraZeneca has agreed to purchase AbelZeta’s 50% stake in the China development and commercialisation rights for C-CAR031.
Novartis has announced plans to construct a radioligand therapy (RLT) manufacturing facility in Winter Park, Florida, as part of its ongoing radioligand therapy manufacturing expansion.
MediLink Therapeutics has signed an exclusive licensing agreement with Roche for the development and commercialisation of YL201, an investigational antibody-drug conjugate (ADC) targeting B7H3 in various solid tumour types.
Samsung Biologics has entered into a definitive agreement, through its subsidiary Samsung Biologics America, to acquire Human Genome Sciences from GSK as part of its plan to expand manufacturing capabilities in the US.
Johnson & Johnson (J&J) has received the US Food and Drug Administration (FDA) approval for Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), a subcutaneously (SC) administered therapy to treat patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).
The European Commission (EC) has approved Incyte’s Minjuvi (tafasitamab) in conjunction with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) who have received a minimum of one systemic therapy line.
Alnylam Pharmaceuticals is set to invest $250m in the expansion of its facility in Norton, Massachusetts, US, to meet the growing global demand for RNA interference (RNAi) therapeutics.
Zealand Pharma and OTR Therapeutics have signed a strategic collaboration and licence agreement aimed at jointly discovering and developing therapies for several targets in metabolic diseases.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.